Japanese Prostate Cancer Imaging Trial Meets Study Objectives MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that...

Japanese Prostate Cancer Imaging Study Completes Enrolment MELBOURNE, Australia and KYOTO, Japan, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the last patient has been imaged in a...

Mr. Ryoichi Tanaka Joins Telix Japan as Chief Operating Officer MELBOURNE, Australia and KYOTO Japan, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that Mr. Ryoichi Tanaka has joined the...

First Patient Dosed in Japanese Prostate Cancer Imaging Study MELBOURNE, Australia and KYOTO, Japan, May 25, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a...